You are here

Open-Label, Extended-Use Study of Xerecept Initiated

EMERYVILLE, Calif., Aug. 25 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI®) (Nasdaq: NTII - News) today announced the enrollment of the first patients in an open-label, extended-use study of XERECEPT® (hCRF). This study is open to all patients who participate in one of the two ongoing blinded, Phase III trials designed to determine the dexamethasone-sparing effects of hCRF in brain tumor patients being treated for peritumoral brain edema.

This extended-use program will collect safety information and allow the treating physicians to attempt a maximum dexamethasone reduction and possible elimination altogether. XERECEPT will be provided to patients until either the drug becomes commercially available or if NTI research in this indication is discontinued.

Dr. Lisa U. Carr, Sr. Vice President and Chief Medical Officer of NTI, said, "We are pleased to offer the extended-use of this potential dexamethasone-sparing agent to patients in all of our trials."

Source: Neurobiological Technologies, Inc.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation